Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northfield Lab(NFLD) -- Ignore unavailable to you. Want to Upgrade?

To: erbob who wrote (73)	7/20/1998 12:11:00 PM
From: borb	Respond to of 148

$34? Do you know their all time high was around $25? What are your supporting points?

To: erbob who wrote (73)	8/5/1998 1:11:00 AM
From: erbob	Read Replies (2) \| Respond to of 148

nfld has shown its hand today in a reuters interview. this company represents the only current, phase 3 blood substitute in progress. it has shown remarkable success in phase 2 at 10 unit dosing and continues with this trauma study as well as phase 3 in high blood loss elective surgery. safety and efficacy have been fully demonstrated in phase 2. phase 3 design was altered from phase 2 at suggestion of fda. however, rapid blood loss is rapid blood loss and efficacy should be easily demonstrated in phase 3 as well. Baxter is out of the picture with hemassist. Cow hemoglobin is frought with peril during rapid infusion. genetically engineered hemoglobin is years away and perflurocarbons are unlikely to reveal high volume rapid infusion characteristics required for hemorrhage. Thus leaving only one company with a several year lead on the rest of the world. at current cost projections of raw materials and production costs (see yahoo board) the value of the company is around $51 per share with a 24 multiple. these are very conservative estimates for a life saving therapy. the next 6 weeks should reveal some good news for nfld and a significant increase from its current valuation.